Immunic Inc

NASDAQ:IMUX  
11.88
+0.29 (+2.50%)
Products, Regulatory

Immunic, Inc. Publishes Positive Results From Phase 1 Clinical Trial Of Imu-935

Published: 12/14/2021 12:28 GMT
Immunic Inc (IMUX) - Immunic, Inc. Publishes Positive Results From the Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of Imu-935, a Potentially Best-in-class Oral Il-17 Inhibitor.
Immunic Inc - Single Daily Dosing Up to 400 Mg and Multiple Daily Dosing of 300 Mg Were Found to Be Safe and Well-tolerated in Healthy Human Subjects.
Immunic - Newly Available Preclinical in Vivo Data Showing That Imu-935 Maintains Normal Thymocyte Maturation in Relevant Acute and Chronic Mouse Models.